

October 14, 2005

Board of Pharmaceutical Specialties
ATTN: Richard J. Bertin, Ph.D., R.Ph.
Executive Director
2215 Constitution Avenue, N.W.
Washington, D.C. 20037-2985

SUBJECT: RECOGNITION OF BOARD

Dear Dr. Bertin:

I am writing in response to your August 18, 2005, September 23, 2005, and October 6, 2005, letters seeking recognition of the Board of Pharmaceutical Specialties certification process for Board Certified Nuclear Pharmacist (BCNP) by the U.S. Nuclear Regulatory Commission (NRC).

NRC staff reviewed your BCNP certification process and determined, based on your October 6, 2005, letter, that it met the applicable requirements in 10 CFR 35.55(a) for NRC recognition as of March 6, 1996. Accordingly, the Board of Pharmaceutical Specialties BCNP certification will be listed on NRC's web site for Part 35 matters, at <http://www.nrc.gov/materials/miau/med-use-toolkit.html> with a recognition date of March 6, 1996.

Please notify the NRC, via letter, 6 months in advance of the Board of Pharmaceutical Specialties plans to discontinue or make changes to your certification procedures for BCNP that would affect the recognition of the Board of Pharmaceutical Specialties BCNP certification process under the requirements of 10 CFR 35.55(a).

For further information or for questions, please contact Donna-Beth Howe, Ph.D. of my staff (301/415-7848, dbh@nrc.gov).

Thomas H. Essig, Chief
Materials Safety and Inspection Branch
Division of Industrial and
Medical Nuclear Safety
Office of Nuclear Material Safety
and Safeguards

October 14, 2005

Board of Pharmaceutical Specialties
ATTN: Richard J. Bertin, Ph.D., R.Ph.
Executive Director
2215 Constitution Avenue, N.W.
Washington, D.C. 20037-2985

SUBJECT: RECOGNITION OF BOARD

Dear Dr. Bertin:

I am writing in response to your August 18, 2005, September 23, 2005, and October 6, 2005, letters seeking recognition of the Board of Pharmaceutical Specialties certification process for Board Certified Nuclear Pharmacist (BCNP) by the U.S. Nuclear Regulatory Commission (NRC).

NRC staff reviewed your BCNP certification process and determined, based on your October 6, 2005, letter, that it met the applicable requirements in 10 CFR 35.55(a) for NRC recognition as of March 6, 1996. Accordingly, the Board of Pharmaceutical Specialties BCNP certification will be listed on NRC's web site for Part 35 matters, at <http://www.nrc.gov/materials/miau/med-use-toolkit.html> with a recognition date of March 6, 1996.

Please notify the NRC, via letter, 6 months in advance of the Board of Pharmaceutical Specialties plans to discontinue or make changes to your certification procedures for BCNP that would affect the recognition of the Board of Pharmaceutical Specialties BCNP certification process under the requirements of 10 CFR 35.55(a).

For further information or for questions, please contact Donna-Beth Howe, Ph.D. of my staff (301/415-7848, dbh@nrc.gov).

/RA/

Thomas H. Essig, Chief
Materials Safety and Inspection Branch
Division of Industrial and
Medical Nuclear Safety
Office of Nuclear Material Safety
and Safeguards

Distribution:

IMNS r/f RidsNmssOd

ML052870256

OFFICE:	MSIB	MSIB	MSIB	MSIB
NAME:	DBHowe	CFlannery	RKaras	TEssig
DATE:	10/12/05	10/12/05	10/13/05	10/14/05

OFFICIAL RECORD COPY